

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 49D2110804	(X3) Date Survey Completed 09/18/2024
Name of Provider or Supplier Vista Medical Center North Arlington	Street Address, City, State 5335 Langston Blvd, Arlington, VA	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D0000	An off-site CLIA proficiency testing (PT) desk review was conducted for Vista Medical Center-North Arlington on September 18, 2024 by the Virginia Department of Health's Office of Licensure and Certification. The laboratory was surveyed under 42 CFR part 493 CLIA Regulations. Specific deficiencies cited are as follows and include the following condition under 42 CFR part 493 CLIA Regulation: D2016 - 42 CFR. 493.803 Condition: Successful Participation.
D2016	<p>SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: Based on a proficiency testing (PT) desk review of the laboratory's Certification and Survey Provider Enhanced Reporting (CASPER)-0155 report, American Proficiency</p>

Institute (API) evaluations for 2023 (Event three) and 2024 (Events one, and two), the laboratory failed to successfully participate in a proficiency testing program approved by Health and Human Services (HHS) for the specialty of Hematology for two of three events reviewed. Refer to D2130.

D2130

HEMATOLOGY
CFR(s): 493.851(f)

Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:
Based on a proficiency testing (PT) off-site desk review of the laboratory's Certification and Survey Provider Enhanced Reporting (CASPER)-0155 report, American Proficiency Institute (API) evaluation reports for 2023 Event three) and 2024 (Events one and two) and interview, the laboratory failed to participate in PT for White Blood Cell count (WBC), Red Blood Cell count (RBC), Hemoglobin (HGB) Hematocrit (HCT), Platelet count (PLT) and WBC Differential (WBC Diff) for two (2) of three (3) hematology testing events resulting in initial unsuccessful PT participation. The findings include: 1. Review of the CASPER-0155 report revealed the following unsatisfactory scores: 2023 Event 3 - WBC, RBC, HGB, HCT, PLT, and Cell ID=0%, 2024 Event 2 - WBC, RBC, HGB, HCT, PLT, and Cell ID=0%, 2. A review of the laboratory's 2023 and 2024 API PT scores for the analytes WBC, RBC, HGB, HCT, PLT, and WBC diff revealed the following unsatisfactory scores: 2023 Event 3 - WBC, RBC, HGB, HCT, PLT, and WBC diff=0%, Unsuccessful, Failure to Participate. 2024 Event 2 - WBC, RBC, HGB, HCT, PLT and WBC diff=0%, Unsuccessful, Failure to Participate. The above findings resulted in initial unsuccessful participation for the analytes listed above. 3. In a telephone interview with the Technical Consultant on September 18, 2024, at approximately 10:10 AM, the findings were confirmed.